MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia

BACKGROUND: Replacement therapy is the most common treatment for reduction of bleeding and control of episodic bleeding in individuals with hemophilia. Despite the proven effectiveness of factor replacement therapy, repeated intravenous administration is a heavy burden to individuals with hemophilia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Heechun, Lee, Sumin, Jo, Seunghyun, Kwon, Young Eun, Kang, Hyunju, Choi, Gahee, Jung, Myung Eun, Kwak, Mi‐Jeong, Kim, Seonghoon, Oh, Byung‐Ha, Kim, Dong‐Sik, Hwang, Sung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles ‐ Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695563/
https://www.ncbi.nlm.nih.gov/pubmed/33313469
http://dx.doi.org/10.1002/rth2.12438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695563/
https://www.ncbi.nlm.nih.gov/pubmed/33313469
http://dx.doi.org/10.1002/rth2.12438

Ejemplares similares